Important new treatment for the most common skin cancer (basal cell carcinoma) called Erivedge (vismodegib)

large chess king The FDA approved a novel new treatment for the most common kind of skin cancer. The drug is called Erivedge (vismodegib) and treats patients with basal cell carcinoma. The drug is intended for use in people with locally advanced basal cell cancer who are not candidates for surgery or radiation and when cancer has spread to other parts of the body (is metastatic).

Some interesting points about Erivedge, is that it was reviewed under the FDA priority review program. This usually means that the agency recognizes that the drug is a novel approach to an important condition, that there are few other treatment options or some combination of atributes.

Ongoing research will reveal the true benefits and risks and you can find more information at www.fda.gov.  

Approval Date: 
Mon, 01/30/2012
Company: 
Genentech/Roche

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.